Inclusion Criteria:

1. Patients who have provided written informed consent

2. Patients who have urothelial cell carcinoma of the bladder with clinically apparent
stage Ta, grade G1-G2 and satisfy both of the following criteria:

- The maximum number of tumors is 5.

- Each tumor diameter: ≤ 3.5 cm.

3. Age: ≥20 years old at enrollment.

4. The functions of the major organs are adequate, and the following test value criteria
are satisfied:

- Neutrophil count ≥1,500/μL

- Platelet count ≥10×10^4/μL

- Hemoglobin ≥10 g/dL

Exclusion Criteria:

1. Patients with a single, primary bladder cancer of <0.5 cm.

2. Patients with CIS lesions in the bladder or a history thereof.

3. Patients with a history of other than stage Ta, histological grade G1 or G2 disease.

4. Patients experiencing recurrence within 4 months following TURBT for prior NMIBC
(duration between the last TURBT and cystoscopic confirmation of the present
recurrence is within 4 months).

5. Patients without at least a three-month cystoscopically confirmed recurrence-free
interval between the last TURBT and the time of study screening

6. Patients having a bladder tumor with a histological diagnosis other than urothelial
carcinoma of the bladder or a history thereof.

7. Patients who had been administered EO9 in the past.

8. Patients who had been administered any other investigational drug within the past 30
days.

9. Patients having a medical condition that would make it unsafe for them to undergo
TURBT under general or spinal anesthesia.